Bioxytran Reports Functional Gains in First CIDP Patient Treated with PLICID
BIXT is trading near its 52-week low of $0.021 (1.9% above the low) on elevated volume (3.0× avg).
Summary
Encouraging clinical observations emerged from the first CIDP patient treated with Bioxytran's AI-designed galectin antagonist PLICID, including improved motor function and no adverse events. The company intends to pursue further clinical evaluation.
Key Events · Product Development and Regulatory · BIXT
-
First CIDP Patient Treated with PLICID
A single CIDP patient treated with once-weekly intravenous PLICID regained finger function and the ability to walk several miles, with no adverse events reported.
-
Novel AI-Designed Galectin Antagonist
PLICID is a complex carbohydrate drug designed through Bioxytran's proprietary Artificial Super Intelligence (ASI) platform, targeting galectins implicated in inflammatory and neurological diseases.
-
Financial Context: Going Concern
The company's last 10-Q (May 2026) reiterated a going concern warning with cash only until September 2026, making further clinical development dependent on additional financing.
-
Next Steps: Larger Clinical Study Planned
Bioxytran intends to pursue further clinical evaluation of PLICID in a larger patient population to further evaluate its therapeutic profile.
Analysis · BIXT · Life Sciences
Bioxytran disclosed the first clinical observations from its PLICID program in CIDP — a single patient regained finger use and the ability to walk miles with no adverse events. While a single-patient observation cannot establish safety or efficacy, the functional improvement in a rare, debilitating neuropathy is a meaningful early signal for a company with a going-concern warning and cash only through September 2026. Positive data could support further development and potential partnering, but the company's precarious financial position means the path to a larger trial is uncertain.
At the time of this filing, BIXT was trading at $0.02 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $0.02 to $0.10. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.